Lucid Diagnostics' shares rose about 30% to $0.42 in Friday's pre-market session. The report gives no company update, so the move alone does not change Lucid's business outlook.
A share-price jump alone does not show that Lucid's sales, products, or finances changed. The report gives no company update to explain the move, so it does not change Lucid's business outlook.
Electra Therapeutics' shares rose about 14% to $10.50 in Friday's pre-market session. The report gives no company update, so the move alone does not change Electra Therapeutics' business outlook.
Alzamend Neuro's shares rose about 12% to $1.25 in Friday's pre-market session. The report gives no company update, so the move alone does not change Alzamend Neuro's business outlook.
Tempest Therapeutics' shares rose about 10% to $0.58 in Friday's pre-market session. The report gives no company update, so the move alone does not change Tempest Therapeutics' business outlook.
PAVmed's shares rose about 10% to $2.25 in Friday's pre-market session. The report gives no company update, so the move alone does not change PAVmed's business outlook.
Evaxion's shares rose about 10% to $4.07 in Friday's pre-market session. The report gives no company update, so the move alone does not change Evaxion's business outlook.
Follow Lucid Diagnostics (LUCD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LUCD